Please login to the form below

Not currently logged in
Email:
Password:

Melior enters new pharmaceutical collaboration

Melior Discovery signs an agreement with Johnson & Johnson Pharmaceutical Research & Development for use of Melior's proprietary theraTRACE indications discovery platform to identify new indications

US-based drug discovery company Melior Discovery has signed an agreement with Johnson & Johnson Pharmaceutical Research & Development (J&JPRD) for use of Melior's proprietary theraTRACE indications discovery platform to identify new indications for multiple J&JPRD drug candidates.

Financial terms were not disclosed.

Melior's theraTRACE platform is a multiplexed set of integrated in-vivo models which quickly identify previously unknown applications for pharmaceutical compounds. It can be applied to discovery, development stage and marketed agents and has already identified novel indications for a number of development stage drugs.

Dr Andrew Reaume, president and CEO of Melior, said of the agreement: "Our theraTRACE indications discovery platform is already proving its value in our existing collaborations with Merck and Pfizer, as well as in screening for our own drug development efforts. We are delighted to be working with J&JPRD, and we look forward to a productive collaboration."

7th August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GEM Marketing Ltd

GEM, a small but perfectly formed integrated marketing agency servicing the pharmaceutical industry....

Latest intelligence

women
Advancing women in healthcare
Fostering the next generation of leaders...
The Challenges Of UX In Healthcare: Technology To Change Lives
Blue Latitude Health Director and Head of Customer Experience Elisa Del Galdo explores the latest digital healthcare trends and reveals the innovations changing the sector today....
It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...

Infographics